C12N 2740/10071
Demonstrated in vivo effect
C12N2740/10071 (Demonstrated in vivo effect) appears on 13 US grants and 19 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 19
- Assignees
- 9
- Inventors
- 28
- Latest grant
- 19 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 1 | 3 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 3 | 2 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 2 | 3 |
| 2023 | 1 | 3 |
| 2024 | 2 | 1 |
| 2025 | 3 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Nucleic acids encoding human endogenous retrovirus K (HERV-k) envelope proteins containing modified immunosuppressive domains (ISD) and uses thereof19 Aug 2025US 12,390,522 B2Inprother Aps
- Vaccine for use in the prophylaxis and/or treatment of a disease1 Apr 2025US 12,263,214 B2Inprother Aps
- Compositions and methods for therapeutic delivery25 Feb 2025US 12,234,475 B2GenVivo, Inc.
- Vaccine for use in the prophylaxis and/or treatment of a disease2 Jul 2024US 12,023,377 B2Inprother Aps
- Vaccine for use in the prophylaxis and/or treatment of a disease30 Jan 2024US 11,883,487 B2Inprother Aps
- Nucleic acids encoding human endogenous retrovirus k (herv-k) envelope proteins containing modified immunosuppressive domains (isd) and uses thereof19 Mar 2026US 2026/0077031 A1Inprother Aps
- Vaccine for use in the prophylaxis and/or treatment of a disease12 Jun 2025US 2025/0186579 A1Inprother Aps
- Compositions and methods for therapeutic delivery10 Apr 2025US 2025/0115930 A1GenVivo, Inc.
- Vaccine for use in the prophylaxis and/or treatment of a disease9 May 2024US 2024/0148860 A1Inprother Aps
- Compositions and methods for therapeutic delivery24 Aug 2023US 2023/0265457 A1GenVivo, Inc.
Most cited
By later US patents